Wikipedia:
Gemeprost
 |
|
|
Gemeprost
|
|
| Systematic (IUPAC) name | |
| methyl
(E)-7-[(1R,2S,3R)-3-hydroxy-2- [(E,3R)-3-hydroxy-4,4-dimethyl-oct-1-enyl]- 5-oxo-cyclopentyl]hept-2-enoate |
|
| Identifiers | |
| CAS number | |
| ATC code | G02 |
| PubChem | |
| Chemical data | |
| Formula | C23H38O5 |
| Mol. mass | 394.545 g/mol |
| SMILES | search in , |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | Pessary |
Gemeprost (16, 16-dimethyl-trans-delta2 PGE1 methyl ester) is an analogue of prostaglandin E1.
Clinical use
In pessary form as the second drug in medical abortion regimen in the UK and Sweden. Gemeprost softens and dilates the cervix and stimulates the uterus to contract.
Side effects
Vaginal bleeding, cramps, nausea, vomiting, loose stools or diarrhea, headache, muscle weakness; dizziness; flushing; chills; backache; dyspnoea; chest pain; palpitations and mild pyrexia. Rare: Uterine rupture, severe hypotension, coronary spasms with subsequent myocardial infarctions.
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)
